Updated views in targeted therapy in the patient with non-small cell lung cancer
MA Ortega, L Pekarek, F Navarro… - Journal of Personalized …, 2023 - mdpi.com
Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents
a set of histological entities that have an ominous long-term prognosis, for example …
a set of histological entities that have an ominous long-term prognosis, for example …
Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA …
D He, H Tang, X Yang, X Liu, Y Zhang… - Frontiers in …, 2023 - frontiersin.org
Background Lung adenocarcinoma (LUAD), the predominant subtype of non-small cell lung
cancer (NSCLC), remains a pervasive global public health concern. Disulfidoptosis, a …
cancer (NSCLC), remains a pervasive global public health concern. Disulfidoptosis, a …
[HTML][HTML] Survivin in lung cancer: a potential target for therapy and prevention—a narrative review
AG Pachimatla, R Fenstermaker… - Translational Lung …, 2024 - ncbi.nlm.nih.gov
Methods The PubMed database and the United States National Library of Medicine search
engine at the National Institutes of Health were searched on 24 August 2023 to identify …
engine at the National Institutes of Health were searched on 24 August 2023 to identify …
m6A‐induced TRIB3 regulates Hippo pathway through interacting with LATS1 to promote the progression of lung adenocarcinoma
J Wu, T Yi, C Zhuo, D Wang, M Zhang… - Journal of Cellular …, 2024 - Wiley Online Library
Recent studies have indicated that dysregulation of the Hippo/Yes‐associated protein (YAP)
axis is associated with tumor progression and therapy resistance in various cancer types …
axis is associated with tumor progression and therapy resistance in various cancer types …
The diagnostic potential role of thioredoxin reductase and TXNRD1 in early lung adenocarcinoma: A cohort study
G Jiang, X Wang, Y Xu, Z He, R Lu, C Song, Y Jin, H Li… - Heliyon, 2024 - cell.com
Background Lung adenocarcinoma (LUAD) is the primary form of lung cancer, yet the
reliable biomarkers for early diagnosis remain insufficient. Thioredoxin reductase (TrxR) is …
reliable biomarkers for early diagnosis remain insufficient. Thioredoxin reductase (TrxR) is …
Efficacy of first‐line treatment options beyond RET‐TKIs in advanced RET‐rearranged non‐small cell lung cancer: A multi‐center real‐world study
Y Ge, J Li, W Gong, J Wang, X Wei, J Liu… - Cancer …, 2024 - Wiley Online Library
Background Although RET‐tyrosine kinase inhibitors (RET‐TKIs) are the preferred first‐line
therapy for advanced RET‐arranged NSCLC, most patients cannot afford them. In this …
therapy for advanced RET‐arranged NSCLC, most patients cannot afford them. In this …
MECOM: a bioinformatics and experimentally identified marker for the diagnosis and prognosis of lung adenocarcinoma
A Li, M Li, J Wang, J Zhou, T Yang, M Fan… - Biomarkers in …, 2024 - Taylor & Francis
Objective: We aimed to explore the clinical value of MDS1 and EVI1 complex locus
(MECOM) in lung adenocarcinoma (LUAD). Methods: Bioinformatics and experimental …
(MECOM) in lung adenocarcinoma (LUAD). Methods: Bioinformatics and experimental …
[PDF][PDF] Advances in combined neuroendocrine carcinoma of lung cancer
Z Han, F Yang, F Wang, H Zheng, X Chen… - Pathology and …, 2024 - por-journal.com
Globally, the morbidity and mortality rates of lung cancer are increasing [1], making it a
significant public health concern and burden for families [2]. Approximately 75% of the 2.20 …
significant public health concern and burden for families [2]. Approximately 75% of the 2.20 …
Construction of an immune-related gene prognostic model with experimental validation and analysis of immune cell infiltration in lung adenocarcinoma
J Yang, C Tang, C Li, X Li, W Yang - Oncology Letters, 2024 - spandidos-publications.com
There is a correlation between tumors and immunity with the degree of immune cell
infiltration in tumors being closely related to tumor growth and progression. Therefore, the …
infiltration in tumors being closely related to tumor growth and progression. Therefore, the …
[HTML][HTML] Tumor volume doubling time as a potential predictor of prognosis in clinical stage I lung squamous cell carcinoma
K Nakahashi, M Nakatsuka, M Endo… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background Tumor volume doubling time (VDT) has been shown to predict prognosis in
various non-small cell lung carcinoma with scant evidence for lung squamous cell …
various non-small cell lung carcinoma with scant evidence for lung squamous cell …